Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We remain focused on advancing our late-stage oncology product candidates towards potential registration. We believe our pipeline and capabilities ...

He knew his airline offered a stripped-down version of what his competitors did—and he was proud of it.

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Discovery World has announced that a new president and CEO will start later this month. The science and technology museum on ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

CVS Health fell short on third-quarter profit, but it posted strong sales and shook up leadership under new CEO David Joyner ...

Havas Health has appointed Anna Maria Marra CEO of Europe. Marra is joining the healthcare agency after a 22-year run at ...

Steve Discher, Founder and CEO of ISP Supplies, added, "For years, WAV and ISP Supplies have worked in a supplier, customer ...

Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We remain focused on advancing our late-stage oncology product candidates towards potential registration. We believe our pipeline and ...

"We remain focused on advancing our late-stage oncology product candidates towards potential registration," said BioNTech's CEO Ugur Sahin. The company is aiming for its first oncology launch in 2026.